Basiliximab (Simulect®) and Daclizumab (Zenapax®)

Nadim Mahmud, Burcin Taner, Nasimul Ahsan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

To function as effector cells, T cells must undergo antigen-stimulated activation that induces synthesis of many lymphokines, including interleukin-2 (IL-2). In certain diseases, a proportion of these stimulated cells will express surface interleukin-2 receptor (IL-2R) alpha peptide, and in these conditions the serum concentration of the soluble form of this peptide is frequently elevated. Such evidence of T cell activation and IL-2R expression appears in the setting of transplant rejections as well as in many neoplastic and autoimmune disorders, thus forming the basis for anti-IL-2-directed therapy in these conditions. In this chapter, we will discuss the potential therapies involving IL-2mAbs in organ transplant and other non-transplant immunologic conditions.

Original languageEnglish (US)
Title of host publicationApproved Therapeutic Antibodies
PublisherWiley Blackwell
Pages1375-1404
Number of pages30
Volume3-4
ISBN (Electronic)9783527682423
ISBN (Print)9783527329373
DOIs
StatePublished - Dec 3 2014

Fingerprint

Transplants
T-cells
Interleukin-2
Chemical activation
Interleukin-2 Receptor alpha Subunit
T-Lymphocytes
Peptides
Lymphokines
Interleukin-2 Receptors
Graft Rejection
Antigens
Therapeutics
Serum
daclizumab
basiliximab

Keywords

  • IL-2 receptor blockers
  • Immunologic diseases
  • Monoclonal antibodies
  • Solid organ
  • Transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mahmud, N., Taner, B., & Ahsan, N. (2014). Basiliximab (Simulect®) and Daclizumab (Zenapax®). In Approved Therapeutic Antibodies (Vol. 3-4, pp. 1375-1404). Wiley Blackwell. https://doi.org/10.1002/9783527682423.ch47

Basiliximab (Simulect®) and Daclizumab (Zenapax®). / Mahmud, Nadim; Taner, Burcin; Ahsan, Nasimul.

Approved Therapeutic Antibodies. Vol. 3-4 Wiley Blackwell, 2014. p. 1375-1404.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mahmud, N, Taner, B & Ahsan, N 2014, Basiliximab (Simulect®) and Daclizumab (Zenapax®). in Approved Therapeutic Antibodies. vol. 3-4, Wiley Blackwell, pp. 1375-1404. https://doi.org/10.1002/9783527682423.ch47
Mahmud N, Taner B, Ahsan N. Basiliximab (Simulect®) and Daclizumab (Zenapax®). In Approved Therapeutic Antibodies. Vol. 3-4. Wiley Blackwell. 2014. p. 1375-1404 https://doi.org/10.1002/9783527682423.ch47
Mahmud, Nadim ; Taner, Burcin ; Ahsan, Nasimul. / Basiliximab (Simulect®) and Daclizumab (Zenapax®). Approved Therapeutic Antibodies. Vol. 3-4 Wiley Blackwell, 2014. pp. 1375-1404
@inbook{47c764e2c8eb4ddda1dcf6b0ea27f401,
title = "Basiliximab (Simulect{\circledR}) and Daclizumab (Zenapax{\circledR})",
abstract = "To function as effector cells, T cells must undergo antigen-stimulated activation that induces synthesis of many lymphokines, including interleukin-2 (IL-2). In certain diseases, a proportion of these stimulated cells will express surface interleukin-2 receptor (IL-2R) alpha peptide, and in these conditions the serum concentration of the soluble form of this peptide is frequently elevated. Such evidence of T cell activation and IL-2R expression appears in the setting of transplant rejections as well as in many neoplastic and autoimmune disorders, thus forming the basis for anti-IL-2-directed therapy in these conditions. In this chapter, we will discuss the potential therapies involving IL-2mAbs in organ transplant and other non-transplant immunologic conditions.",
keywords = "IL-2 receptor blockers, Immunologic diseases, Monoclonal antibodies, Solid organ, Transplantation",
author = "Nadim Mahmud and Burcin Taner and Nasimul Ahsan",
year = "2014",
month = "12",
day = "3",
doi = "10.1002/9783527682423.ch47",
language = "English (US)",
isbn = "9783527329373",
volume = "3-4",
pages = "1375--1404",
booktitle = "Approved Therapeutic Antibodies",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Basiliximab (Simulect®) and Daclizumab (Zenapax®)

AU - Mahmud, Nadim

AU - Taner, Burcin

AU - Ahsan, Nasimul

PY - 2014/12/3

Y1 - 2014/12/3

N2 - To function as effector cells, T cells must undergo antigen-stimulated activation that induces synthesis of many lymphokines, including interleukin-2 (IL-2). In certain diseases, a proportion of these stimulated cells will express surface interleukin-2 receptor (IL-2R) alpha peptide, and in these conditions the serum concentration of the soluble form of this peptide is frequently elevated. Such evidence of T cell activation and IL-2R expression appears in the setting of transplant rejections as well as in many neoplastic and autoimmune disorders, thus forming the basis for anti-IL-2-directed therapy in these conditions. In this chapter, we will discuss the potential therapies involving IL-2mAbs in organ transplant and other non-transplant immunologic conditions.

AB - To function as effector cells, T cells must undergo antigen-stimulated activation that induces synthesis of many lymphokines, including interleukin-2 (IL-2). In certain diseases, a proportion of these stimulated cells will express surface interleukin-2 receptor (IL-2R) alpha peptide, and in these conditions the serum concentration of the soluble form of this peptide is frequently elevated. Such evidence of T cell activation and IL-2R expression appears in the setting of transplant rejections as well as in many neoplastic and autoimmune disorders, thus forming the basis for anti-IL-2-directed therapy in these conditions. In this chapter, we will discuss the potential therapies involving IL-2mAbs in organ transplant and other non-transplant immunologic conditions.

KW - IL-2 receptor blockers

KW - Immunologic diseases

KW - Monoclonal antibodies

KW - Solid organ

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84940851619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940851619&partnerID=8YFLogxK

U2 - 10.1002/9783527682423.ch47

DO - 10.1002/9783527682423.ch47

M3 - Chapter

SN - 9783527329373

VL - 3-4

SP - 1375

EP - 1404

BT - Approved Therapeutic Antibodies

PB - Wiley Blackwell

ER -